A landmark trial published in The Lancet found that once-weekly semaglutide, the medication marketed as Ozempic, significantly reduced heavy-drinking days among people with alcohol use disorder and obesity.
Ozempic Can Curb Cravings in Alcohol Use Disorder, Landmark Trial Finds